Aptose Biosciences Inc. announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase I/II clinical trial of tuspetinib , an oral, mutation agnostic tyrosine kinase inhibitor being developed for the treatment of patients with relapsed or refractory AML.
[Aptose Bioscience, Inc.]
